Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions

References

• Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16(3), 448–458 (2001).
   PubMed Web of Science ®Google Scholar
• Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov. Disord. 20(2), 224–230 (2005).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Deckers F, Lehert P. Parkinson’s disease home diary: further validation and implications for clinical trials. Mov. Disord. 19(12), 1409–1413 (2004).
   PubMed Web of Science ®Google Scholar
• Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson’s disease: review of recent trials. Mov. Disord. 28(2), 131–144 (2013).
   PubMed Web of Science ®Google Scholar
• Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson’s disease. Trends Neurosci. 29(11), 647–654 (2006).
   PubMed Web of Science ®Google Scholar
• Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 147(1), 90–95 (1999).
   PubMed Web of Science ®Google Scholar
• Kanda T, Jackson MJ, Smith LA et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 43(4), 507–513 (1998).
   PubMed Web of Science ®Google Scholar
• Abstracts of the 8th International Congress of Parkinson’s Disease and Movement Disorders. June 14-17, 2004. Rome, Italy. Mov. Disord. 19(Suppl. 9), S1–S491 (2004).
   Google Scholar
• LeWitt PA, Guttman M, Tetrud JW et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann. Neurol. 63(3), 295–302 (2008).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Shulman LM, Trugman JM et al. Study of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuations. Mov. Disord. 23(15), 2177–2185 (2008).
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M; Japanese Istradefylline Study Group. Clinical efficacy of istradefylline (KW-6002) in Parkinson’s disease: a randomized, controlled study. Mov. Disord. 25(10), 1437–1443 (2010).
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Kondo T; Japanese Istradefylline Study Group. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease. Mov. Disord. 28(8), 1138–1141 (2013).
   PubMed Web of Science ®Google Scholar
• Pourcher E, Fernandez HH, Stacy M, Mori A, Ballerini R, Chaikin P. Istradefylline for Parkinson’s disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat. Disord. 18(2), 178–184 (2012).
   PubMed Web of Science ®Google Scholar
• Factor S, Mark MH, Watts R et al. A long-term study of istradefylline in subjects with fluctuating Parkinson’s disease. Parkinsonism Relat. Disord. 16(6), 423–426 (2010).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Cantillon M, Pourcher E et al. Preladenant in patients with Parkinson’s disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol. 10(3), 221–229 (2011).
   PubMed Web of Science ®Google Scholar
• Factor SA, Wolski K, Togasaki DM et al. Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson’s disease. Mov. Disord. 28(6), 817–820 (2013).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Borgohain R, Onofrj M et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson’s disease patients. Mov. Disord. 27(1), 106–112 (2012).
   PubMed Web of Science ®Google Scholar
• Barone P, Fernandez H, Ferreira J et al. Safinamide as an add-on therapy to a stable dose of a single dopamine agonist: results from a randomized, placebo-controlled, 24-week multicenter trial in early idiopathic Parkinson disease (PD) patients (MOTION Study). Neurology 80 (Meeting Abstracts 1), P01.061 (2013).
   Google Scholar
• Schapira AH, Fox S, Hauser R et al. Safinamide add on to L-dopa: a randomized, placebo-controlled, 24-week global trial in patients with Parkin- son’s disease (PD) and motor fluctuations (SETTLE). Neurology 80 (Meeting Abstracts 1), P01.062 (2013).
   Google Scholar
• Gregoire L, Jourdain VA, Townsend M, Roach A, Di Paolo T. Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat. Disord. 19(5), 508–514 (2013).
   PubMed Web of Science ®Google Scholar
• Murata M, Hasegawa K, Kanazawa I; Japan Zonisamide on PDSG. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 68(1), 45–50 (2007).
   PubMed Web of Science ®Google Scholar
• Mochio S, Sengoku R, Kono Y et al. Actigraphic study of tremor before and after treatment with zonisamide in patients with Parkinson’s disease. Parkinsonism Relat. Disord. 18(7), 906–908 (2012).
   PubMedGoogle Scholar
• Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat. Rev. Neurosci. 9(9), 665–677 (2008).
   PubMed Web of Science ®Google Scholar
• Snow BJ, Macdonald L, McAuley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double-blind, placebo-controlled study. Clin. Neuropharmacol. 23(2), 82–85 (2000).
   PubMed Web of Science ®Google Scholar
• Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 75(1), 141–143 (2004).
   PubMed Web of Science ®Google Scholar
• Wolf E, Seppi K, Katzenschlager R et al. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov. Disord. 25(10), 1357–1363 (2010).
   PubMed Web of Science ®Google Scholar
• Gasparini F, Di Paolo T, Gomez-Mancilla B. Metabotropic glutamate receptors for Parkinson’s disease therapy. Parkinsons Dis. 2013, 196028 (2013).
   PubMedGoogle Scholar
• Lees A, Fahn S, Eggert KM et al. Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson’s disease. Mov. Disord. 27(2), 284–288 (2012).
   PubMed Web of Science ®Google Scholar
• Rascol O, Barone P, Behari M et al. Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin. Neuropharmacol. 35(1), 15–20 (2012).
   PubMed Web of Science ®Google Scholar
• Clarke CE, Cooper JA, Holdich TA, Group TS. A randomized, double-blind, placebo-controlled, ascending-dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson’s disease with response fluctuations. Clin. Neuropharmacol. 24(3), 133–138 (2001).
   PubMed Web of Science ®Google Scholar
• Shoulson I, Penney J, McDermott M et al. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson’s disease. Neurology 56(4), 455–462 (2001).
   PubMed Web of Science ®Google Scholar
• Mela F, Marti M, Dekundy A, Danysz W, Morari M, Cenci MA. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease. J. Neurochem. 101(2), 483–497 (2007).
   PubMedGoogle Scholar
• Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson’s disease. J. Pharmacol. Exp. Ther. 333(3), 865–873 (2010).
   PubMed Web of Science ®Google Scholar
• Berg D, Godau J, Trenkwalder C et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov. Disord. 26(7), 1243–1250 (2011).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Rascol O, Destee A et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov. Disord. (2013).
   Google Scholar
• Barnum CJ, Bhide N, Lindenbach D et al. Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by alpha- and beta-adrenergic receptor antagonists in hemiparkinsonian rats. Pharmacol. Biochem. Behav. 100(3), 607–615 (2012).
   PubMed Web of Science ®Google Scholar
• Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov. Disord. 20(8), 919–931 (2005).
   PubMed Web of Science ®Google Scholar
• Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson’s disease. Brain Res. 510(1), 104–107 (1990).
   PubMedGoogle Scholar
• Hill MP, Brotchie JM. The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat. Br. J. Pharmacol. 128(7), 1577–1585 (1999).
   PubMedGoogle Scholar
• Srinivasan J, Schmidt WJ. The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action? Naunyn Schmiedebergs Arch. Pharmacol. 369(6), 629–638 (2004).
   PubMedGoogle Scholar
• Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson’s disease. Mov. Disord. 14(5), 744–753 (1999).
   PubMed Web of Science ®Google Scholar
• Savola JM, Hill M, Engstrom M et al. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson’s disease. Mov. Disord. 18(8), 872–883 (2003).
   PubMed Web of Science ®Google Scholar
• Lewitt PA, Hauser RA, Lu M et al. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 79(2), 163–169 (2012).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Damier P, Goetz CG et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin. Neuropharmacol. 27(2), 58–62 (2004).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Damier P, Hicking C et al. Sarizotan as a treatment for dyskinesias in Parkinson’s disease: a double-blind placebo-controlled trial. Mov. Disord. 22(2), 179–186 (2007).
   PubMed Web of Science ®Google Scholar
• Pahwa R, Factor SA, Lyons KE et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 66(7), 983–995 (2006).
   PubMed Web of Science ®Google Scholar
• Calandrella D, Antonini A. Pulsatile or continuous dopaminomimetic strategies in Parkinson’s disease. Parkinsonism Relat. Disord. 18(Suppl. 1), S120–S122 (2012).
   PubMedGoogle Scholar
• Katzenschlager R, Hughes A, Evans A et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges. Mov. Disord. 20(2), 151–157 (2005).
   PubMed Web of Science ®Google Scholar
• Cereceda-Balic F, Kleist E, Prast H, Schlimper H, Engel H, Gunther K. Description and evaluation of a sampling system for long-time monitoring of PAHs wet deposition. Chemosphere 49(3), 331–340 (2002).
   PubMedGoogle Scholar
• van Laar T, van der Geest R, Danhof M, Bodde HE, Goossens PH, Roos RA. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson’s disease. Clin. Neuropharmacol. 21(3), 152–158 (1998).
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF, Gutmann L, Hull KL, Jr., Bottini PB, Sherry JH, Investigators APOS. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Relat. Disord. 13(2), 93–100 (2007).
   PubMed Web of Science ®Google Scholar
• De Gaspari D, Siri C, Landi A et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J. Neurol. Neurosurg. Psychiatry 77(4), 450–453 (2006).
   PubMed Web of Science ®Google Scholar
• Tyne HL, Parsons J, Sinnott A, Fox SH, Fletcher NA, Steiger MJ. A 10 year retrospective audit of long-term apomorphine use in Parkinson’s disease. J. Neurol. 251(11), 1370–1374 (2004).
   PubMed Web of Science ®Google Scholar
• Antonini A, Odin P. Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson’s disease. Parkinsonism Relat. Disord. 15(Suppl. 4), S97–S100 (2009).
   PubMedGoogle Scholar
• Pahwa R, Stacy MA, Factor SA et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68(14), 1108–1115 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang J, Zhang X et al. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson’s disease: a multicenter, double-blind, randomized, placebo-controlled study. Parkinsonism Relat. Disord. 19(11), 1022–1026 (2013).
   PubMed Web of Science ®Google Scholar
• Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68(4), 272–276 (2007).
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Lyons KE, Pahwa R, Group SPS. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 68(16), 1262–1267 (2007).
   PubMed Web of Science ®Google Scholar
• Schapira AH, Barone P, Hauser RA et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology 77(8), 767–774 (2011).
   PubMed Web of Science ®Google Scholar
• Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson’s disease. Expert Opin. Pharmacother. 8(5), 657–664 (2007).
   PubMed Web of Science ®Google Scholar
• Nyholm D, Nilsson Remahl AI, Dizdar N et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64(2), 216–223 (2005).
   PubMed Web of Science ®Google Scholar
• Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson’s disease. Expert Rev. Neurother. 6(10), 1403–1411 (2006).
   PubMedGoogle Scholar
• Fernandez HH, Odin P. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson’s disease. Curr. Med. Res. Opin. 27(5), 907–919 (2011).
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Vanagunas A, Odin P et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease open-label study: interim results. Parkinsonism Relat. Disord. 19(3), 339–345 (2013).
   PubMed Web of Science ®Google Scholar
• Djaldetti R, Giladi N, Hassin-Baer S, Shabtai H, Melamed E. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson’s disease: an open-label, randomized, crossover study. Clin. Neuropharmacol. 26(6), 322–326 (2003).
   PubMed Web of Science ®Google Scholar
• Juncos JL, Mouradian MM, Fabbrini G, Serrati C, Chase TN. Levodopa methyl ester treatment of Parkinson’s disease. Neurology 37(7), 1242–1245 (1987).
   PubMedGoogle Scholar
• Lewitt PA, Ellenbogen A, Chen D et al. Actively transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations. Clin. Neuropharmacol. 35(3), 103–110 (2012).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Ellenbogen AL, Metman LV et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson’s disease. Mov. Disord. 26(12), 2246–2252 (2011).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Hsu A, Kell S et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 12(4), 346–356 (2013).
   PubMed Web of Science ®Google Scholar
• Weaver FM, Follett K, Stern M et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 301(1), 63–73 (2009).
   PubMed Web of Science ®Google Scholar
• Williams A, Gill S, Varma T et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol. 9(6), 581–591 (2010).
   PubMed Web of Science ®Google Scholar
• Deuschl G, Schade-Brittinger C, Krack P et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N. Engl. J. Med. 355(9), 896–908 (2006).
   PubMed Web of Science ®Google Scholar
• Moro E, Lozano AM, Pollak P et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson’s disease. Mov. Disord. 25(5), 578–586 (2010).
   PubMed Web of Science ®Google Scholar
• Follett KA, Weaver FM, Stern M et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N. Engl. J. Med. 362(22), 2077–2091 (2010).
   PubMed Web of Science ®Google Scholar
• Duker AP, Espay AJ. Surgical treatment of Parkinson disease: past, present, and future. Neurol. Clin. 31(3), 799–808 (2013).
   PubMed Web of Science ®Google Scholar
• Rosin B, Slovik M, Mitelman R et al. Closed-loop deep brain stimulation is superior in ameliorating parkinsonism. Neuron 72(2), 370–384 (2011).
   PubMed Web of Science ®Google Scholar
• Gross RE, McDougal ME. Technological advances in the surgical treatment of movement disorders. Curr. Neurol. Neurosci. Rep. 13(8), 371 (2013).
   PubMedGoogle Scholar
• Schuepbach WM, Rau J, Knudsen K et al. Neurostimulation for Parkinson’s disease with early motor complications. N. Engl. J. Med. 368(7), 610–622 (2013).
   PubMed Web of Science ®Google Scholar
• Santos-Garcia D, de la Fuente-Fernandez R. Impact of non-motor symptoms on the quality of life of patients with Parkinson’s disease: some questions beyond research findings. J. Neurol. Sci. (2013) ( Epub ahead of print).
   Google Scholar
• Chaudhuri KR, Martinez-Martin P, Schapira AH et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov. Disord. 21(7), 916–923 (2006).
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Martinez-Martin P, Brown RG et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov. Disord. 22(13), 1901–1911 (2007).
   PubMed Web of Science ®Google Scholar
• Honig H, Antonini A, Martinez-Martin P et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov. Disord. 24(10), 1468–1474 (2009).
   PubMed Web of Science ®Google Scholar
• Pursiainen V, Lyytinen J, Pekkonen E. Effect of duodenal levodopa infusion on blood pressure and sweating. Acta Neurol. Scand. 126(4), e20–e24 (2012).
   PubMed Web of Science ®Google Scholar
• Ray Chaudhuri K, Martinez-Martin P, Antonini A et al. Rotigotine and specific non-motor symptoms of Parkinson’s disease: post hoc analysis of RECOVER. Parkinsonism Relat. Disord. 19(7), 660–665 (2013).
   PubMed Web of Science ®Google Scholar